Paroxetine
Panic Disorder
Beijing Tongren HospitalSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Panic Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal University of South Florida | Phase 4 | BBB |
Seroquel® Centre for Addiction and Mental Health | Phase 4 | BB |
ZIPRASIDONE VA Palo Alto Health Care System | Phase 4 | BB |
Valproic Acid University of South Florida | Phase 4 | BB |
Sertraline Hamilton Health Sciences Corporation | Phase 4 | BB |
Alprazolam National Institute on Drug Abuse (NIDA) | Phase 2 | B |
Isoproterenol Laureate Institute for Brain Research, Inc. | N/A | D |
MELIPRAMINE Northwell Health | N/A | D |
Same molecule, other indications
Paroxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →